Search

Your search keyword '"Svetina, Petra"' showing total 11 results
Start Over Author "Svetina, Petra"
11 results on '"Svetina, Petra"'

1. Availability and costs of medicines for the treatment of tuberculosis in Europe

Author

Hasan Hafizi, Khachatryan, Naira, Aroyan, Harut, Kabasakalyan, Eduard, Knappik, Michael, Skrahina, Alena, Klimuk, Dzmitry, Nikolenka, Alena, Muylle, Inge, Milanov, Vladimir, Velkovska, Desislava, Tarinska, Neli, Bachiyska, Elizabeta, Jankovic, Mateja, Pieridou, Despo, Adamide, Tonia, Nicolaou, Nicos, Vasakova, Martina, Sukholytka, Mariia, Kopeckà, Emilia, Folkvardsen, Dorte Bek, Svensson, Erik, Danilovits, Manfred, Kummik, Tiina, Vasankari, Tuula, Fréchet-Jachym, Mathilde, Nahmiash, Audrey, Togonidze, Tamar, Avaliani, Zaza, Kinkladze, Inga, Aspindzelashvili, Rusudan, Bichashvili, Teona, Losaberidze, Gulnazi, Merabishvili, Tsitsino, Kalsdorf, Barbara, Manika, Katerina, Tsiakitzis, Karyofyllis, Bakos, Agnes, Ægisdóttir, Tinna Rán, Michelsen, Guðrún Svanhvít, Karlsdóttir, Kristín, McLaughlin, Anne-Marie, Fitzgibbon, Margaret, Chemtob, Daniel, Codecasa, Luigi R., Ferrarese, Maurizio, Torri, Stefania, Gjocaj, Majlinda, Kuksa, Liga, Davidaviciene, Edita, Wirtz, Gil, Perrin, Monique, Asciak, Analita Pace, Chesov, Dumitri, de Lange, Wiel, Akkerman, Onno, Poposka, Biljana Ilievska, Mack, Ulrich, Jensenius, Mogens, Kvalvik, Lajla, Mengshoel, Anne Torunn, Kruczak, Katarzyna, Duarte, Raquel, Ribeiro, Nadine, Ibraim, Elmira, Kaluzhenina, Anna, Barkanova, Olga, Pesut, Dragica, Solovic, Ivan, Svetina, Petra, Souza-Galvão, Maria-Luiza de, Millet, Joan-Pau, Casas, Xavi, Vives, Montserrat, Bruchfeld, Judith, Dalemo, Paulina, Jonsson, Jerker, Aeschbacher, Katrin, Keller, Peter, Özkara, Seref, Tiberi, Simon, Chen, Christabelle, Terleeva, Yana, Dudnyk, Andrii, Günther, Gunar, Guglielmetti, Lorenzo, Leu, Claude, Lange, Christoph, and van Leth, Frank

Published
2023
Full Text
View/download PDF

2. Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe

Author

Günther, Gunar, primary, Guglielmetti, Lorenzo, additional, Kherabi, Yousra, additional, Duarte, Raquel, additional, Lange, Christoph, additional, Adamides, Tonia, additional, Akkerman, Onno, additional, Andersen, Aase Bengaard, additional, Bakos, Ágnes, additional, Bjarnason, Agnar, additional, Bruchfeld, Judith, additional, Chesov, Dumitru, additional, Codecasa, Luigi Ruffo, additional, Cirillo, Daniela, additional, Danilovits, Manfred, additional, Davidavičienė, Edita, additional, De Souza Galvão, Maria Luiza, additional, Garnier, Sandrine, additional, Gjocaj, Majlinda, additional, Günther, Gunar, additional, Ibraim, Elmira, additional, Kappnik, Michael, additional, Khachatryan, Naira, additional, Klimuk, Dzmitry, additional, Kuksa, Liga, additional, Jachym, Mathilde Frechet, additional, Josefsdottir, Kamilla, additional, Kaluzhenina, Anna, additional, Mack, Ulrich, additional, Makek, Mateja Jankovic, additional, Manika, Katerina, additional, Mclaughlin, Anne- Marie, additional, Mema, Donika, additional, Mengshoel, Anne Torunn, additional, Muylle, Inge, additional, Nanovic, Zorica, additional, Özkara, Şeref, additional, Perl, Sivan, additional, Pesut, Dragica, additional, Pierdou, Despo, additional, Ryskulov, Galym, additional, Skowroński, Marcin, additional, Solovic, Ivan, additional, Sukholytka, Mariia, additional, Svetina, Petra, additional, Terleeva, Yana, additional, Tiberi, Simon, additional, Togonidze, Tamara, additional, Torri, Stefania, additional, Turaev, Laziz, additional, Usmanova, Ruzilya, additional, Wirtz, Gil, additional, Vasankari, Tuula, additional, and Zhdanova, Elena, additional

Published
2024
Full Text
View/download PDF

3. Availability and costs of medicines for the treatment of tuberculosis in Europe

Author

Günther, Gunar, Guglielmetti, Lorenzo, Leu, Claude, Lange, Christoph, van Leth, Frank, Hafizi, Hasan, Khachatryan, Naira, Aroyan, Harut, Kabasakalyan, Eduard, Knappik, Michael, Skrahina, Alena, Klimuk, Dzmitry, Nikolenka, Alena, Muylle, Inge, Milanov, Vladimir, Velkovska, Desislava, Tarinska, Neli, Bachiyska, Elizabeta, Jankovic, Mateja, Pieridou, Despo, Adamide, Tonia, Nicolaou, Nicos, Vasakova, Martina, Sukholytka, Mariia, Kopeckà, Emilia, Andersen, Åse Bengård, Folkvardsen, Dorte Bek, Svensson, Erik, Danilovits, Manfred, Kummik, Tiina, Vasankari, Tuula, Fréchet-Jachym, Mathilde, Nahmiash, Audrey, Togonidze, Tamar, Avaliani, Zaza, Kinkladze, Inga, Aspindzelashvili, Rusudan, Bichashvili, Teona, Losaberidze, Gulnazi, Merabishvili, Tsitsino, Kalsdorf, Barbara, Manika, Katerina, Tsiakitzis, Karyofyllis, Bakos, Agnes, Ægisdóttir, Tinna Rán, Michelsen, Guðrún Svanhvít, Karlsdóttir, Kristín, McLaughlin, Anne-Marie, Fitzgibbon, Margaret, Chemtob, Daniel, Codecasa, Luigi R., Ferrarese, Maurizio, Torri, Stefania, Gjocaj, Majlinda, Kuksa, Liga, Davidaviciene, Edita, Wirtz, Gil, Perrin, Monique, Asciak, Analita Pace, Chesov, Dumitri, de Lange, Wiel, Akkerman, Onno, Poposka, Biljana Ilievska, Mack, Ulrich, Jensenius, Mogens, Kvalvik, Lajla, Mengshoel, Anne Torunn, Kruczak, Katarzyna, Duarte, Raquel, Ribeiro, Nadine, Ibraim, Elmira, Kaluzhenina, Anna, Barkanova, Olga, Pesut, Dragica, Solovic, Ivan, Svetina, Petra, Souza-Galvão, Maria-Luiza de, Millet, Joan-Pau, Casas, Xavi, Vives, Montserrat, Bruchfeld, Judith, Dalemo, Paulina, Jonsson, Jerker, Aeschbacher, Katrin, Keller, Peter, Özkara, Seref, Tiberi, Simon, Chen, Christabelle, Terleeva, Yana, Dudnyk, Andrii, Health Economics and Health Technology Assessment, APH - Global Health, APH - Methodology, and Microbes in Health and Disease (MHD)

Subjects
Microbiology (medical), Evropa, Extensively Drug-Resistant Tuberculosis, Antitubercular Agents, Capacity building, 610 Medicine & health, MDR-TB, Mycobacterium tuberculosis - terapija z zdravili, Microbial Sensitivity Tests, Antimicrobial resistance, Medicines, Mycobacterium tuberculosis - drug therapy, SDG 3 - Good Health and Well-being, Tuberculosis, Multidrug-Resistant, Humans, Tuberculosis, tuberkuloza - terapija z zdravili, health care costs - drug therapy, Mycobacterium tuberculosis, General Medicine, END-TB strategy, udc:616-002, tuberculosis - drug therapy, Costs, stroški zdravstvene oskrbe - terapija z zdravili, Europe, Infectious Diseases, Availability of medicines
Abstract

Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines in European countries.Methods: We investigated the access to genotypic and phenotypic Mycobacterium tuberculosis drug susceptibility testing and the availability of antituberculosis drugs and calculated the cost of drugs and treatment regimens at major tuberculosis treatment centres in countries of the WHO European region where rates of drug-resistant tuberculosis are the highest among all WHO regions. Results were stratified by middle-income and high-income countries.Results: Overall, 43 treatment centres from 43 countries participated in the study. For WHO group A drugs, the frequency of countries with the availability of phenotypic drug susceptibility testing was as follows: (a) 75% (30/40) for levofloxacin, (b) 82% (33/40) for moxifloxacin, (c) 48% (19/40) for bedaquiline, and (d) 72% (29/40) for linezolid. Overall, of the 43 countries, 36 (84%) and 24 (56%) countries had access to bedaquiline and delamanid, respectively, whereas only 6 (14%) countries had access to rifapentine. The treatment of patients with extensively drug-resistant tuberculosis with a regimen including a carbapenem was available only in 17 (40%) of the 43 countries. The median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicin-resistant tuberculosis (shorter regimen, including bedaquiline for 6 months), and extensively drug-resistant tuberculosis (including bedaquiline, delamanid, and a carbapenem) were €44 (minimum–maximum, €15–152), €764 (minimum–maximum, €542–15152), and €8709 (minimum–maximum, €7965–11759) in middle-income countries (n = 12) and €280 (minimum–maximum, €78–1084), €29765 (minimum–maximum, €11116–40584), and €217591 (minimum–maximum, €82827–320146) in high-income countries (n = 29), respectively.Discussion: In countries of the WHO European region, there is a widespread lack of drug susceptibility testing capacity to new and repurposed antituberculosis drugs, lack of access to essential medications in several countries, and a high cost for the treatment of drug-resistant tuberculosis.

Published
2023

4. Tuberculosis incidence in foreign-born people residing in European countries in 2020

Author

Vasiliu, Anca, Köhler, Niklas, Altpeter, Ekkehardt, Ægisdóttir, Tinna Rán, Amerali, Marina, de Oñate, Wouter Arrazola, Bakos, Ágnes, D'Amato, Stefania, Cirillo, Daniela Maria, van Crevel, Reinout, Davidaviciene, Edita, Demuth, Irène, Domínguez, Jose, Duarte, Raquel, Günther, Gunar, Guthmann, Jean-Paul, Hatzianastasiou, Sophia, Holm, Louise Hedevang, Herrador, Zaida, Hribar, Urška, Huberty, Conny, Ibraim, Elmira, Jackson, Sarah, Jensenius, Mogens, Josefsdottir, Kamilla Sigridur, Koch, Anders, Korzeniewska-Kosela, Maria, Kuksa, Liga, Kunst, Heinke, Lienhardt, Christian, Mahler, Beatrice, Makek, Mateja Janković, Muylle, Inge, Normark, Johan, Pace-Asciak, Analita, Petrović, Goranka, Pieridou, Despo, Russo, Giulia, Rzhepishevska, Olena, Salzer, Helmut J. F., Marques, Marta Sá, Schmid, Daniela, Solovic, Ivan, Sukholytka, Mariya, Svetina, Petra, Tyufekchieva, Mariya, Vasankari, Tuula, Viiklepp, Piret, Villand, Kersti, Wallenfels, Jiri, Wesolowski, Stefan, Mandalakas, Anna-Maria, Martinez, Leonardo, Zenner, Dominik, Lange, Christoph, Vasiliu, Anca, Köhler, Niklas, Altpeter, Ekkehardt, Ægisdóttir, Tinna Rán, Amerali, Marina, de Oñate, Wouter Arrazola, Bakos, Ágnes, D'Amato, Stefania, Cirillo, Daniela Maria, van Crevel, Reinout, Davidaviciene, Edita, Demuth, Irène, Domínguez, Jose, Duarte, Raquel, Günther, Gunar, Guthmann, Jean-Paul, Hatzianastasiou, Sophia, Holm, Louise Hedevang, Herrador, Zaida, Hribar, Urška, Huberty, Conny, Ibraim, Elmira, Jackson, Sarah, Jensenius, Mogens, Josefsdottir, Kamilla Sigridur, Koch, Anders, Korzeniewska-Kosela, Maria, Kuksa, Liga, Kunst, Heinke, Lienhardt, Christian, Mahler, Beatrice, Makek, Mateja Janković, Muylle, Inge, Normark, Johan, Pace-Asciak, Analita, Petrović, Goranka, Pieridou, Despo, Russo, Giulia, Rzhepishevska, Olena, Salzer, Helmut J. F., Marques, Marta Sá, Schmid, Daniela, Solovic, Ivan, Sukholytka, Mariya, Svetina, Petra, Tyufekchieva, Mariya, Vasankari, Tuula, Viiklepp, Piret, Villand, Kersti, Wallenfels, Jiri, Wesolowski, Stefan, Mandalakas, Anna-Maria, Martinez, Leonardo, Zenner, Dominik, and Lange, Christoph

Abstract

Background: European-specific policies for tuberculosis (TB) elimination require identification of key populations that benefit from TB screening. Aim: We aimed to identify groups of foreign-born individuals residing in European countries that benefit most from targeted TB prevention screening. Methods: The Tuberculosis Network European Trials group collected, by cross-sectional survey, numbers of foreign-born TB patients residing in European Union (EU) countries, Iceland, Norway, Switzerland and the United Kingdom (UK) in 2020 from the 10 highest ranked countries of origin in terms of TB cases in each country of residence. Tuberculosis incidence rates (IRs) in countries of residence were compared with countries of origin. Results: Data on 9,116 foreign-born TB patients in 30 countries of residence were collected. Main countries of origin were Eritrea, India, Pakistan, Morocco, Romania and Somalia. Tuberculosis IRs were highest in patients of Eritrean and Somali origin in Greece and Malta (both > 1,000/100,000) and lowest among Ukrainian patients in Poland (3.6/100,000). They were mainly lower in countries of residence than countries of origin. However, IRs among Eritreans and Somalis in Greece and Malta were five times higher than in Eritrea and Somalia. Similarly, IRs among Eritreans in Germany, the Netherlands and the UK were four times higher than in Eritrea. Conclusions: Country of origin TB IR is an insufficient indicator when targeting foreign-born populations for active case finding or TB prevention policies in the countries covered here. Elimination strategies should be informed by regularly collected country-specific data to address rapidly changing epidemiology and associated risks.

Published
2023
Full Text
View/download PDF

5. Immunophenotypes of anti-SARS-CoV-2 responses associated with fatal COVID-19

Author

Šelb, Julij, primary, Bitežnik, Barbara, additional, Bidovec Stojković, Urška, additional, Rituper, Boštjan, additional, Osolnik, Katarina, additional, Kopač, Peter, additional, Svetina, Petra, additional, Cerk Porenta, Kristina, additional, Šifrer, Franc, additional, Lorber, Petra, additional, Trinkaus Leiler, Darinka, additional, Hafner, Tomaž, additional, Jerič, Tina, additional, Marčun, Robert, additional, Lalek, Nika, additional, Frelih, Nina, additional, Bizjak, Mojca, additional, Lombar, Rok, additional, Nikolić, Vesna, additional, Adamič, Katja, additional, Mohorčič, Katja, additional, Grm Zupan, Sanja, additional, Šarc, Irena, additional, Debeljak, Jerneja, additional, Koren, Ana, additional, Ajda, Demšar Luzar MSc, additional, Rijavec, Matija, additional, Kern, Izidor, additional, Fležar, Matjaž, additional, Rozman, Aleš, additional, and Korošec, Peter, additional

Published
2022
Full Text
View/download PDF

6. Completeness of tuberculosis (TB) notification: inventory studies and capture-recapture analyses, six European Union countries, 2014 to 2016

Author

Straetemans, Masja, Bakker, Mirjam I, Alba, Sandra, Mergenthaler, Christina, Rood, Ente, Andersen, Peter H, Schimmel, Henrieke, Simunovic, Aleksandar, Svetina, Petra, Carvalho, Carlos, Lyytikäinen, Outi, Abubakar, Ibrahim, Harris, Ross J, Ködmön, Csaba, van der Werf, Marieke J, and van Hest, Rob

Subjects
Portugal, tuberculosis, Croatia, statistics, Denmark, Slovenia, surveillance, epidemiology, Finland, Netherlands
Published
2020

7. Completeness of tuberculosis (TB) notification: inventory studies and capture-recapture analyses, six European Union countries, 2014 to 2016

Author

Straetemans, Masja, primary, Bakker, Mirjam I, additional, Alba, Sandra, additional, Mergenthaler, Christina, additional, Rood, Ente, additional, Andersen, Peter H, additional, Schimmel, Henrieke, additional, Simunovic, Aleksandar, additional, Svetina, Petra, additional, Carvalho, Carlos, additional, Lyytikäinen, Outi, additional, Abubakar, Ibrahim, additional, Harris, Ross J, additional, Ködmön, Csaba, additional, van der Werf, Marieke J, additional, and van Hest, Rob, additional

Published
2020
Full Text
View/download PDF

9. Razvoj blagovne znamke Združenja Manager

Author

Svetina, Petra and Pfajfar, Gregor

Subjects
corporate identity, vision, primeri, research, identiteta podjetja, udc:339.138, blagovne znamke, vizija, brands, cases, marketing, image, Združenje Manager, raziskave, trženje
Published
2017

11. Tuberculosis incidence in foreign-born people residing in European countries in 2020.

Author

Vasiliu A, Köhler N, Altpeter E, Ægisdóttir TR, Amerali M, de Oñate WA, Bakos Á, D'Amato S, Cirillo DM, van Crevel R, Davidaviciene E, Demuth I, Domínguez J, Duarte R, Günther G, Guthmann JP, Hatzianastasiou S, Holm LH, Herrador Z, Hribar U, Huberty C, Ibraim E, Jackson S, Jensenius M, Josefsdottir KS, Koch A, Korzeniewska-Kosela M, Kuksa L, Kunst H, Lienhardt C, Mahler B, Makek MJ, Muylle I, Normark J, Pace-Asciak A, Petrović G, Pieridou D, Russo G, Rzhepishevska O, Salzer HJF, Marques MS, Schmid D, Solovic I, Sukholytka M, Svetina P, Tyufekchieva M, Vasankari T, Viiklepp P, Villand K, Wallenfels J, Wesolowski S, Mandalakas AM, Martinez L, Zenner D, and Lange C

Subjects
Humans, Incidence, Cross-Sectional Studies, Somalia, Europe epidemiology, Tuberculosis diagnosis, Tuberculosis epidemiology
Abstract

BackgroundEuropean-specific policies for tuberculosis (TB) elimination require identification of key populations that benefit from TB screening.AimWe aimed to identify groups of foreign-born individuals residing in European countries that benefit most from targeted TB prevention screening.MethodsThe Tuberculosis Network European Trials group collected, by cross-sectional survey, numbers of foreign-born TB patients residing in European Union (EU) countries, Iceland, Norway, Switzerland and the United Kingdom (UK) in 2020 from the 10 highest ranked countries of origin in terms of TB cases in each country of residence. Tuberculosis incidence rates (IRs) in countries of residence were compared with countries of origin.ResultsData on 9,116 foreign-born TB patients in 30 countries of residence were collected. Main countries of origin were Eritrea, India, Pakistan, Morocco, Romania and Somalia. Tuberculosis IRs were highest in patients of Eritrean and Somali origin in Greece and Malta (both > 1,000/100,000) and lowest among Ukrainian patients in Poland (3.6/100,000). They were mainly lower in countries of residence than countries of origin. However, IRs among Eritreans and Somalis in Greece and Malta were five times higher than in Eritrea and Somalia. Similarly, IRs among Eritreans in Germany, the Netherlands and the UK were four times higher than in Eritrea.ConclusionsCountry of origin TB IR is an insufficient indicator when targeting foreign-born populations for active case finding or TB prevention policies in the countries covered here. Elimination strategies should be informed by regularly collected country-specific data to address rapidly changing epidemiology and associated risks.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results